More Efficient Tools to Realize Information for Consumers Act or the METRIC Act
This bill requires prescription drug manufacturers to report, and the Department of Health and Human Services (HHS) to publish, specified information related to prescription drug pricing and the pharmaceutical supply chain. Specifically, HHS must publish reports submitted by drug manufacturers that include the percentage of any wholesale drug price increase that is greater than 10% in one calendar year (or 25% over three consecutive years), an explanation for the price increase, and other data. HHS must enter agreements with other agencies, research organizations, and public and private health insurers to share data submitted to HHS by drug manufacturers about the identity and quantity of drug sample requests by health practitioners.
HHS also must publish online aggregate data reported by pharmacy benefits managers (PBMs), including the percentage of prescriptions provided by mail-order, rate that generic versions of drugs are dispensed, and aggregate discounts, rebates, or price concessions negotiated.
The bill requires the Federal Trade Commission to report about potentially anticompetitive practices by PBMs such as steering patients to certain pharmacies or designing price formulas that increase the market share of higher priced drugs, among other information. The report also must include recommendations to increase transparency and deter anticompetitive behavior.
The bill further requires Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that provides prescribers with patient-specific formulary and benefit information. Additionally, the bill expands certain price reporting requirements for prescription drug payments under Medicare.
More Efficient Tools to Realize Information for Consumers Act
Bill journey · stage 2 of 5
Under committee review
What it doesSummary reported to house (Sep 24, 2019)
More Efficient Tools to Realize Information for Consumers Act or the METRIC Act
This bill requires prescription drug manufacturers to report, and the Department of Health and Human Services (HHS) to publish, specified information related to prescription drug pricing and the pharmaceutical supply chain. Specifically, HHS must publish reports submitted by drug manufacturers that include the percentage of any wholesale drug price increase that is greater than 10% in one calendar year (or 25% over three consecutive years), an explanation for the price increase, and other data. HHS must enter agreements with other agencies, research organizations, and public and private health insurers to share data submitted to HHS by drug manufacturers about the identity and quantity of drug sample requests by health practitioners.
HHS also must publish online aggregate data reported by pharmacy benefits managers (PBMs), including the percentage of prescriptions provided by mail-order, rate that generic versions of drugs are dispensed, and aggregate discounts, rebates, or price concessions negotiated.
The bill requires the Federal Trade Commission to report about potentially anticompetitive practices by PBMs such as steering patients to certain pharmacies or designing price formulas that increase the market share of higher priced drugs, among other information. The report also must include recommendations to increase transparency and deter anticompetitive behavior.
The bill further requires Medicare prescription drug plan sponsors to implement an electronic, real-time benefit tool that provides prescribers with patient-specific formulary and benefit information. Additionally, the bill expands certain price reporting requirements for prescription drug payments under Medicare.
What just happenedSep 24, 2019
Placed on the Union Calendar, Calendar No. 170.
Who’s behind it
- Reported in HouseSep 24, 2019
- Introduced in HouseApr 12, 2019
- Sep 24, 2019CalendarsH12410
Placed on the Union Calendar, Calendar No. 170.
- Sep 24, 2019CommitteeH12200
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-215.
Energy and Commerce Committee - Sep 24, 2019Committee5000
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 116-215.
Energy and Commerce Committee - Jul 17, 2019Committee
Ordered to be Reported (Amended) by Voice Vote.
Energy and Commerce Committee - Jul 17, 2019Committee
Committee Consideration and Mark-up Session Held.
Energy and Commerce Committee - Jul 11, 2019Committee
Forwarded by Subcommittee to Full Committee (Amended) by Voice Vote .
Health Subcommittee - Jul 11, 2019Committee
Subcommittee Consideration and Mark-up Session Held.
Health Subcommittee - May 21, 2019Committee
Subcommittee Hearings Held.
Health Subcommittee - Apr 15, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 12, 2019IntroReferralH11100
Referred to the House Committee on Energy and Commerce.
Energy and Commerce Committee - Apr 12, 2019IntroReferralIntro-H
Introduced in House
- Apr 12, 2019IntroReferral1000
Introduced in House
Fair Accountability and Innovative Research Drug Pricing Act of 2019 or the FAIR Drug Pricing Act of 2019
This bill requires manufacturers to report about certain price increases for prescription drugs and biological products with a wholesale cost of at least $100 per month. Such reports must include, among other information (1) the percentage price increase, (2) a justification for such increase, (3) the price history of the drug, (4) the total cost to develop the drug, and (5) the total revenue and net profit generated from the drug.